Verrica Pharmaceuticals Inc. VRCA
2.83 USD -0.38 (-11.70%)
As ofNov 17, 2026, 1:55 PM EST
2.77 Day range 3.66
2.77 52-week range 9.82
- YTD
- -65.94%
- 1 year
- -24.13%
News
seekingalpha.com Verrica Pharmaceuticals Inc. (VRCA) Q3 2026 Earnings Call Transcript Verrica Pharmaceuticals Inc. (VRCA) Q3 2026 Earnings Call Transcript
marketbeat.com Verrica Pharmaceuticals Q3 Earnings Call Highlights Verrica Pharmaceuticals NASDAQ: VRCA reported record quarterly U.S. revenue for its molluscum treatment YCANTH in the third quarter of 2026, even as total revenue fell from a year earlier and its net…
globenewswire.com Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results – Company reports record U.S. YCANTH net product revenue of $5.7 million in Q3 2026, up 11.9% over the previous quarter and 57.9% year-over-year, and total revenue of $6.9 million –
globenewswire.com Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London WEST CHESTER, Pa., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of…
